US8039435 — Melanocortin receptor ligands
Composition of Matter · Assigned to Ipsen Pharma SAS · Expires 2032-08-21 · 6y remaining
What this patent protects
This patent protects compounds that act as ligands for melanocortin receptors and their pharmaceutically-acceptable salts, including the active drug substance SETMELANOTIDE ACETATE.
USPTO Abstract
The present invention is directed to compounds according to formula, (R 2 R 3 )-A 1 - c (A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 )-A 10 -R 1 , and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.